We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Daurismo

News List

Pfizer gets EC approval for Daurismo to treat newly diagnosed acute myeloid leukaemia pharmaceutical-business-review
July 02, 2020
Pfizer has secured approval from the European Commission (EC) for its Daurismo (glasdegib) to treat certain adult patients with newly diagnosed acute myeloid leukaemia (AML).
CHMP puts eight new medicines forward for approval pharmatimes
May 06, 2020
The European Medicines Agency's human medicines committee (CHMP) has put forward eight medicines for approval at its April meeting.
FDA Approves DAURISMO with Cytarabine for AML americanpharmaceuticalreview
December 28, 2018
he U.S. Food and Drug Administration (FDA) approved DAURISMO (glasdegib), in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in .....
Pfizer doubles down in AML with Daurismo approval fiercepharma
November 28, 2018
Make that four drug approvals for Pfizer’s oncology unit in less than two months. In a welcome streak for the pharma giant—what with Lyrica generics looming—the FDA handed out a go-ahead for Daurismo, a treatment for acute myeloid leukemia.